| $337M | ||
| $259M | ||
| $79M | ||
| $58M | ||
| $50M | ||
| $50M |
Buys | $59,999,962 | 1 | 2 |
Sells | $21,602,028 | 47 | 98 |
| Schroeder Thilo | director | 1 | $60M | 0 | $0 | $60M |
| Wei Lin | Chief Medical Officer | 0 | $0 | 1 | $208,954 | $-208,954 |
| Weber Barbara | director | 0 | $0 | 1 | $249,716 | $-249,716 |
| Patel Sushil | director | 0 | $0 | 2 | $365,535 | $-365,535 |
| Anders Jack | Chief Financial Officer | 0 | $0 | 5 | $865,316 | $-865,316 |
| Cislini Jeff | General Counsel | 0 | $0 | 11 | $1.41M | $-1.41M |
| Horn Margaret A | Chief Operating Officer | 0 | $0 | 5 | $3.19M | $-3.19M |
| Kelsey Stephen Michael | See Remarks | 0 | $0 | 12 | $5.48M | $-5.48M |
| GOLDSMITH MARK A | See Remarks | 0 | $0 | 10 | $9.83M | $-9.83M |
Revolution Medicines, Inc., a clinical-stage precision oncology company, focuses on developing therapies to inhibit frontier targets in RAS-addicted cancers. The company is developing RMC-4630, an inhibitor of SHP2, which is in Phase 1/2 clinical trial for the treatment of solid tumors, such as gynecologic and colorectal cancer tumors. It also develops RMC-5845, a selective inhibitor of SOS1, a protein that converts RAS (OFF) to RAS (ON) in cells; and RMC-5552, a hyperactivated selective inhibitor of mTORC1 signaling in tumors. In addition, the company is developing RMC-6291, a mutant-selective inhibitor of KRASG12C(ON) and NRASG12C(ON); and RMC-6236, a RAS-selective inhibitor of multiple RAS(ON) variants. Further, it develops RAS(ON) Inhibitors targeting KRASG13C(ON) and KRASG12D(ON). The company has a collaboration agreement with Sanofi for the research and development of SHP2 inhibitors, including RMC-4630. Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.
Over the last 12 months, insiders at Revolution Medicines, Inc. have bought $60M and sold $21.6M worth of Revolution Medicines, Inc. stock.
On average, over the past 5 years, insiders at Revolution Medicines, Inc. have bought $27.27M and sold $88.29M worth of stock each year.
Highest buying activity among insiders over the last 12 months: Schroeder Thilo (director) — $60M.
The last purchase of 1,304,347 shares for transaction amount of $60M was made by Schroeder Thilo (director) on 2024‑12‑05.
| 2025-03-20 | Sale | Cislini Jeff | General Counsel | 2,041 0.0011% | $38.71 | $79,008 | +0.42% | |
| 2025-03-17 | Sale | GOLDSMITH MARK A | See Remarks | 11,738 0.0063% | $39.04 | $458,255 | -1.23% | |
| 2025-03-17 | Sale | Kelsey Stephen Michael | See Remarks | 3,294 0.0018% | $39.04 | $128,599 | -1.23% | |
| 2025-03-17 | Sale | Horn Margaret A | Chief Operating Officer | 3,058 0.0016% | $39.04 | $119,385 | -1.23% | |
| 2025-03-17 | Sale | Anders Jack | Chief Financial Officer | 1,864 0.001% | $39.04 | $72,771 | -1.23% | |
| 2025-03-17 | Sale | Cislini Jeff | General Counsel | 1,458 0.0008% | $39.04 | $56,921 | -1.23% | |
| 2025-01-21 | Sale | Cislini Jeff | General Counsel | 2,406 0.0013% | $40.50 | $97,443 | -1.37% | |
| 2024-12-16 | Sale | GOLDSMITH MARK A | See Remarks | 11,714 0.0065% | $45.40 | $531,860 | -9.65% | |
| 2024-12-16 | Sale | Kelsey Stephen Michael | See Remarks | 4,663 0.0026% | $45.40 | $211,718 | -9.65% | |
| 2024-12-16 | Sale | Horn Margaret A | Chief Operating Officer | 4,329 0.0024% | $45.40 | $196,553 | -9.65% | |
| 2024-12-16 | Sale | Anders Jack | Chief Financial Officer | 2,635 0.0015% | $45.40 | $119,639 | -9.65% | |
| 2024-12-16 | Sale | Cislini Jeff | General Counsel | 1,599 0.0009% | $45.40 | $72,601 | -9.65% | |
| 2024-12-05 | Schroeder Thilo | director | 1.3M 0.7544% | $46.00 | $60M | -14.14% | ||
| 2024-11-15 | Sale | Cislini Jeff | General Counsel | 2,554 0.0015% | $55.13 | $140,811 | -26.11% | |
| 2024-11-13 | Sale | Kelsey Stephen Michael | See Remarks | 16,666 0.0099% | $58.65 | $977,509 | -29.92% | |
| 2024-11-06 | Sale | Cislini Jeff | General Counsel | 6,000 0.0037% | $60.00 | $360,000 | -31.13% | |
| 2024-11-04 | Sale | GOLDSMITH MARK A | See Remarks | 50,900 0.0301% | $55.56 | $2.83M | -26.76% | |
| 2024-11-01 | Sale | GOLDSMITH MARK A | See Remarks | 19,100 0.0114% | $55.02 | $1.05M | -25.72% | |
| 2024-10-31 | Sale | Patel Sushil | director | 5,000 0.003% | $54.14 | $270,715 | -23.51% | |
| 2024-10-14 | Sale | Kelsey Stephen Michael | See Remarks | 16,666 0.0113% | $49.49 | $824,804 | -16.14% |
| Schroeder Thilo | director | 2096612 1.1256% | $85.1M | 15 | 0 | +9.36% |
| GOLDSMITH MARK A | See Remarks | 441564 0.2371% | $17.92M | 0 | 40 | |
| Kelsey Stephen Michael | See Remarks | 293051 0.1573% | $11.89M | 0 | 47 | |
| Horn Margaret A | Chief Operating Officer | 153533 0.0824% | $6.23M | 0 | 30 | |
| Anders Jack | Chief Financial Officer | 115006 0.0617% | $4.67M | 0 | 20 | |
| Wei Lin | Chief Medical Officer | 70851 0.038% | $2.88M | 0 | 1 | |
| Cislini Jeff | General Counsel | 57723 0.031% | $2.34M | 0 | 21 | |
| Patel Sushil | director | 19948 0.0107% | $809,689.32 | 0 | 3 | |
| Weber Barbara | director | 13065 0.007% | $530,308.35 | 0 | 10 | |
| TEPPER ROBERT I | 5104130 2.7402% | $207.18M | 0 | 1 | ||
| COLUMN GROUP III, LP | 10 percent owner | 2151026 1.1548% | $87.31M | 0 | 1 | |
| Svennilson Peter | director | 1571963 0.8439% | $63.81M | 0 | 9 | |
| Flynn James E | 10 percent owner | 1297589 0.6966% | $52.67M | 1 | 0 | +14.18% |
| Kim Lorence H. | 60500 0.0325% | $2.46M | 1 | 0 | +5.12% | |
| Wang Xiaolin | See Remarks | 58813 0.0316% | $2.39M | 0 | 7 | |
| ANDERSON ELIZABETH M | director | 26990 0.0145% | $1.1M | 0 | 3 | |
| Miller Vincent A. | director | 20133 0.0108% | $817,198.47 | 0 | 5 | |
| Third Rock Ventures II, L.P. | 10 percent owner | 0 0% | $0 | 0 | 4 | |
| Exter Neil | 0 0% | $0 | 0 | 3 |
$961,890,236 | 276 | 22.46% | $13.11B | |
$159,914,414 | 243 | 18.52% | $7.43B | |
$211,610,344 | 91 | 38.45% | $6.56B | |
$2,765,836 | 72 | 20.00% | $10.78B | |
$108,876,545 | 67 | 72.81% | $6.65B | |
$88,307,390 | 38 | -1.70% | $6.57B | |
$13,655,378 | 35 | 17.13% | $12.78B | |
$15,169,821 | 35 | 70.30% | $11.34B | |
$415,105,240 | 19 | -14.04% | $7.55B | |
Revolution Medicines, Inc. (RVMD) | $83,065,496 | 16 | 9.40% | $7.56B |
$1,345,573 | 16 | 15.45% | $5.48B | |
$103,741 | 9 | 49.60% | $5.66B | |
$948,235 | 8 | 15.55% | $7.92B | |
$2,246,813 | 6 | 70.15% | $5.72B | |
$105,414,951 | 5 | 10.07% | $5.62B | |
$40,276,273 | 4 | 34.57% | $7.7B | |
$4,849,105 | 4 | 2.71% | $8.26B | |
$6,678,053 | 3 | 30.56% | $7.84B | |
$999,989 | 1 | 262.16% | $10.31B |
| Increased Positions | 153 | +48.57% | 27M | +14.08% |
| Decreased Positions | 133 | -42.22% | 13M | -6.97% |
| New Positions | 56 | New | 16M | New |
| Sold Out Positions | 43 | Sold Out | 2M | Sold Out |
| Total Postitions | 335 | +6.35% | 204M | +7.11% |
| Vanguard Group Inc | $696,168.00 | 9.19% | 17.1M | +2M | +14.65% | 2024-12-31 |
| Blackrock, Inc. | $598,274.00 | 7.9% | 14.69M | -27,156 | -0.18% | 2025-03-31 |
| Farallon Capital Management Llc | $539,487.00 | 7.12% | 13.25M | +2M | +17.06% | 2024-12-31 |
| Wellington Management Group Llp | $440,659.00 | 5.82% | 10.82M | -579,703 | -5.08% | 2024-12-31 |
| Janus Henderson Group Plc | $386,188.00 | 5.1% | 9.48M | +3M | +54.53% | 2024-12-31 |
| Baker Bros. Advisors Lp | $323,194.00 | 4.27% | 7.94M | +367,882 | +4.86% | 2024-12-31 |
| Nextech Invest Ltd. | $309,516.00 | 4.09% | 7.6M | +1M | +20.71% | 2024-12-31 |
| Fmr Llc | $274,538.00 | 3.63% | 6.74M | +866,190 | +14.74% | 2024-12-31 |
| Paradigm Biocapital Advisors Lp | $266,843.00 | 3.52% | 6.55M | +1M | +23.32% | 2024-12-31 |
| Price T Rowe Associates Inc /Md/ | $238,862.00 | 3.15% | 5.87M | +552,657 | +10.4% | 2024-12-31 |